Aspecthera is a pre-clinical stage pharmaceutical company developing a non-invasive eye-drop therapy for diabetic retinopathy, a leading cause of vision loss on a global scale. The company was spun-out of the University of Tasmania in 2024 with support from UTAS InVent (Innovation Ventures). Our patient-centric candidate eye-drop therapy is highly differentiated from the current standard-of-care, which involves a burdensome intravitreal (eye injection) treatment paradigm, and also shows promise for early-stage disease intervention filling a large unmet medical need.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Aspecthera Questions
Aspecthera's LinkedIn profile is https://www.linkedin.com/company/aspecthera
Aspecthera's industry is
Biotechnology Research
Aspecthera's top competitors are
Anaxis Pharma,
Progenis Pharmaceuticals,
Venstra Medical,
Theia Medical Pty Ltd,
Wavewise Analytics (Formerly Cyban),
Endo Axiom,
Cathrx,
Inosi Therapeutics Pty Ltd,
Zip Diagnostics,
Nanomedx.
Aspecthera's categories are Biotechnology Research
Aspecthera's founding year is 2024
